Laboratory studies have described a higher risk of tissue toxicity with the use of bupivacaine > procaine > tetracaine > ropivacaine 22.
En estudios de laboratorio, se ha descrito mayor riesgo de toxicidad tisular con el uso de bupivacaína > procaína > tetracaína > ropivacaí-na 22.